Manufacturing uncertainty: Contested science and the protection of the public's health and environment

American Journal of Public Health

Volumn 95, Issue SUPPL. 1, 2005, Pages

  Michaels, David ^a   Monforton, Celeste ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; LEAD;

CHEMICAL INDUSTRY; DANGEROUS GOODS; DECISION MAKING; ENVIRONMENTAL PROTECTION; POLICY; PUBLIC HEALTH; REVIEW; SCIENCE; TOBACCO INDUSTRY;

ENVIRONMENTAL EXPOSURE; GOVERNMENT REGULATION; HUMANS; INDUSTRY; LIABILITY, LEGAL; PUBLIC HEALTH; SCIENCE; SUPREME COURT DECISIONS; UNCERTAINTY; UNITED STATES;

EID: 22744440214     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.2004.043059     Document Type: Review

References (110)

1. Belay E, Bresee J, Holman R, Khan A, Shahriari A, Schonberger L. Reye's syndrome in the United States from 1981 through 1997. N Engl J Med. 1999;340: 1377-1382.
2. Hurwitz E, Barrett M, Bregman D, et al. Public health service study of Reye's syndrome and medications: Report of the main study. JAMA. 1987;257: 1905-1911.
3. Goldman L. Epidemiology in the regulatory arena. Am J Epidemiol. 2001;154:S18-S26.
4. Davis D, Buffler P. Reduction of deaths after drug labeling for risk of Reye's syndrome. Lancet. 1992; 340:1042.
5. Monto A. The disappearance of Reye's syndrome: a public health triumph. N Engl J Med. 1999;340: 1423-1424.
6. Hilts P. Protecting America's Health. New York, NY: Alfred A. Knopf; 2003.
7. 47 Federal Register 57886 (1982). Labeling for salicylate-containing products, advanced notice of proposed rulemaking, Food and Drug Administration, December 28, 1982.
8. Lurie P, Wolfe S. Aspirin and Reye's syndrome. In: Lurie P, Cary D, Tanio C, Wolfe S, Paradigms for Change: A Public Health Textbook for Medical, Dental, Pharmacy and Nursing Students. Washington, DC: Public Citizen's Health Research Group (unpublished).
9. Tenth Report on Carcinogens. US Department of Health and Human Services, National Toxicology Program. Available at: http://ehp.niehs.nih.gov/roc/toc10. html. Accessed December 4, 2003.
10. Waddell W. Public comment, as reported in the Report of Carcinogens Subcommittee Meeting, National Toxicology Program Board of Scientific Counselors. December 2-3, 1998. http://ntp.niehs.nih.gov/index.cfm? objectid=06F3F9F7-0DEB-D47E-C4A683A074666360. Accessed March 14, 2005.
11. Roth HD. Public comment, as reported in the Report of Carcinogens Subcommittee Meeting, National Toxicology Program Board of Scientific Counselors, January 20-21, 2000. http://ntp.niehs.nih.gov/index.cfm? objectid=06F5398C-F235-2FF4-F5DAF01B3FB43BD7. Accessed March 15, 2005.
12. Trichopoulos D. Public comment, as reported in the Report of Carcinogens Subcommittee Meeting, National Toxicology Program Board of Scientific Counselors, January 20-21, 2000. http://ntp.niehs.nih.gov/index.cfm? objectid=06F5398C-F235-2FF4-F5DAF01B3FB43BD7. Accessed March 15, 2005.
13. Glenn R. Public comment, as reported in the Report of Carcinogens Subcommittee Meeting, National Toxicology Program Board of Scientific Counselors, December 2-3, 1998. http://ntp.niehs.nih.gov/index.cfm? objectid=06F3F9F7-0DEB-D47E-C4A683A074666360, Accessed March 14, 2005.
14. Moll W. Public comment, as reported in the Report of Carcinogens Subcommittee Meeting, National Toxicology Program Board of Scientific Counselors, December 2-3, 1998. http://ntp.niehs.nih.gov/index.cfm?objectid= 06F3F9F7-0DEB-D47E-C4A683A074666360, Accessed March 14, 2005.
15. Preston J. Public comment, as reported in the Report of Carcinogens Subcommittee Meeting, National Toxicology Program Board of Scientific Counselors, December 2-3, 1998. http://ntp.niehs.nih.gov/index.cfm?objectid= 06F3F9F7-0DEB-D47E-C4A683A074666360, Accessed March 14, 2005.
16. Teta MJ. Public comment, as reported in the Report of Carcinogens Subcommittee Meeting, National Toxicology Program Board of Scientific Counselors, December 2-3, 1998. http://ntp.niehs.nih.gov/index.cfm?objectid= 06F3F9F7-0DEB-D47E-C4A683A074666360, Accessed March 14, 2005.
17. Schotland S. Public comment, as reported in the Report of Carcinogens Subcommittee Meeting, National Toxicology Program Board of Scientific Counselors, December 2-3, 1998. http://ntp.niehs.nih.gov/index.cfm?objectid= 06F3F9F7-0DEB-D47E-C4A683A074666360. Accessed March 14, 2005.
18. Oller A. Public comment, as reported in the Report of Carcinogens Subcommittee Meeting, National Toxicology Program Board of Scientific Counselors, December 2-3, 1998. http://ntp.niehs.nih.gov/index.cfm?objectid= 06F3F9F7-0DEB-D47E-C4A683A074666360, Accessed March 14, 2005.
19. Blot W. Public comment, as reported in the Report of Carcinogens Subcommittee Meeting, National Toxicology Program Board of Scientific Counselors, December 13-15, 2000. Available at: http://ntp-server. niehs.nih.gov/htdocs/Liason/121300.pdf. Accessed December 3, 2003.
20. International Agency for Research on Cancer. Overall evaluations of carcinogenicity to humans. Available at: http://monographs.iarc.fr/monoeval/ crthgr01. html. Accessed May 29, 2003.
21. Ross S. Public comment, as reported in the Report of Carcinogens Subcommittee Meeting, National Toxicology Program Board of Scientific Counselors, December 13-15, 2000. Available at: http://ntp-server.niehs. nih.gov/htdocs/Liason/121300.pdf. Accessed December 3, 2003.
22. Smith D. Public comment, as reported in the Report of Carcinogens Subcommittee Meeting, National Toxicology Program Board of Scientific Counselors, December 13-15, 2000. Available at: http://ntp-server. niehs.nih.gov/htdocs/Liason/121300.pdf. Accessed December 3, 2003.
23. Deveney J. Public comment, as reported in the Report of Carcinogens Subcommittee Meeting, National Toxicology Program Board of Scientific Counselors, December 13-15, 2000. Available at: http://ntp-server. niehs.nih.gov/htdocs/Liason/121300.pdf. Accessed December 3, 2003.
24. Ozonoff D. On being careful what we wish for: some difficulties with operationalizing the Precautionary Principle. Int J Occup Med Environ Health. 2004; 17(1):35-41.
25. Ozonoff D. Anthrax: the precautionary principle goes postal. Public Health Rep. 2002;117(6):513-520.
26. Daubert v Merrell Dow Pharmaceuticals, Inc. 113 S.Ct. 2786 (1993).
27. Daubert: the most influential Supreme Court ruling you've never heard of. Available at: http://www. defendingscience.org. Accessed August 1, 2004.
28. §515 of the Consolidated Appropriations Act of 2001, P.L. 106-554.
29. Smoking and Health: A Report of the Advisory Committee to the Surgeon General of the Public Health Service. Washington, DC: US Department of Health, Education, and Welfare; 1964. DHEW publication 1103.
30. Smoking and Health: A Report of the Surgeon General, Washington, DC: US Department of Health, Education, and Welfare; 1979. DHEW publication 79-50066.
31. Women and Smoking 2001: A Report of the Surgeon General. Washington, DC: US Department of Health and Human Services; 2001.
32. Kessler D. A Question of Intent: A Great American Battle with a Deadly Industry. New York, NY: Public Affairs; 2001.
33. Glantz S, Slade J, Bero L, Hanauer P, Barnes D. The Cigarette Papers. Berkeley: University of California Press; 1996.
34. Kluger R. Ashes to Ashes: America's Hundred-Year Cigarette War. the Public Health, and the Unabashed Triumph of Philip Morris. New York, NY: Random House; 1996.
35. Confidential Public Relations Report to the TIRC, November 3, 1955. Lorillard Document 82106862-82106866. Available at: http://tobaccodocuments.org/ lor. Accessed December 4, 2004.
36. Hill and Knowlton. Public Relations Proposal for the Tobacco Industry (draft for discussion). July 9, 1959. RJ Reynolds Document 502051941-502051954. Available at: http://tobaccodocuments.org/rjr. Accessed December 4, 2004.
37. Thompson C. Memorandum to William Kloepfer, Jr, and the Tobacco Institute, Inc, from Hill and Knowlton, Inc; October 18, 1968. Tobacco Institute Document T1MN0071488-1491. Available at: http://tobaccodocuments.org/ti. Accessed December 15, 2004.
38. Smoking and Health Proposal. Brown & Williamson Document No. 332506. Available at: http://tobaccodocuments.org/bw. Accessed December 11, 2004.
39. Proctor RN. Should medical historians be working for the tobacco industry? Lancet. 2004;363:1174-1175.
40. Markowitz G, Rosner D. Industry challenges to the principle of prevention in public health: the precautionary principle in historical perspective. Public Health Rep. 2002;117(6):501-512.
41. Proctor RN. Cancer Wars: How Politics Shapes What We Know and Don't Know About Cancer. New York, NY: Basic Books, 1995.
42. Markowitz G, Rosner D. Deceit and Denial: The Deadly Politics of Industrial Pollution. Berkeley: University of California Press; 2002.
43. Markowitz G, Rosner D. "Cater to the children": the role of the lead industry in a public health tragedy, 1900-1955. Am J Public Health. 2000;90(1):36-46.
44. Warren C. Brush with Death: A Social History of Lead Poisoning. Baltimore, Md: Johns Hopkins University Press; 2000.
45. Wilson, BS. Legislative history of the Pesticides Residues Amendment of 1954 and the Delaney Gause of the Food Additives Amendment of 1958. In: Regulating Pesticides in Food: The Delaney Paradox. Washington, DC: National Academies Press; 1987.
46. Jackson M. Subject: Manufacturing Chemists' Association; Hill and Knowlton, Inc, memo to John W. Hill. August 1, 1951.
47. Minutes of the Meeting of Directors of the Manufacturing Chemists' Association, Inc 1951-1952. Chemical Industry Archives of the Environmental Working Group. Available at: http://www.chemicalindustryarchives.org, Accessed December 4, 2003.
48. Miller K. The Voice of Business: Hill and Knowlton and Postwar Public Relations. Chapel Hill: University of North Carolina Press; 1999.
49. Castleman B. Asbestos: Medical and Legal Aspects. New York, NY: Harcourt Brace Jovanovich; 1984.
50. Brodeur P. Outrageous Misconduct: The Asbestos Industry on Trial. New York, NY: Pantheon Books; 1985.
51. Ozonoff D. Failed warnings: asbestos-related disease and industrial medicine. In: Bayer R, ed., Case Studies in the Politics of Professional Responsibility. New York, NY: Oxford University Press, 1988.
52. Egilman D, Fehnel C, Bohme SR. Exposing the "myth" of ABC, "anything but chrysotile": a critique of the Canadian asbestos mining industry and McGill University chrysotile studies. Am J Ind Med. 2003;44: 540-57.
53. Marder H. (senior vice president, Hill and Knowlton) Letter to James E. Gulick, vice president, Brush Wellman, Inc; Attachment entitled: Division of Scientific, Technical and Environmental Affairs; February 21, 1989.
54. Cranor CF. Regulating Toxic Substances: A Philosophy of Science and the Law. New York, NY: Oxford University Press, 1993.
55. Michaels D. Waiting for the body count: corporate decision making and bladder cancer in the U.S. dye industry. Med Anthro Q. 1988;2:215-232.
56. Michaels D. When science isn't enough: Wilhelm Hueper, Robert A. M. Case and the limits of scientific evidence in preventing occupational bladder cancer. Int J Occup Environ Health. 1995;1:278-288.
57. 39 Federal Register 3756. (1974).
58. Part 1910, Occupational Safety and Health Standards, Carcinogens. Vol 39, No. 20, January 29, 1974, page 3756.
59. Comments on the production and use of benzidine, SOCMA Benzidine Task Force, March 9, 1973.
60. Morgan DL, of Cleary, Gottlieb, Steen & Hamilton, on behalf of domestic manufacturers or users of 3,3′-Dichlorobenzidine. Comments to OSHAs Standards Advisory Committee on Carcinogens [Letter]; June 26, 1973.
61. DCB Subcommittee of the Dry Color Manufacturers' Association. Comments to OSHA on the Use of Dichlorobenzidine, March 9, 1973 [Docket H003, Exhibit 2-8].
62. Hueper WC. Occupational and Environmental Cancers of the Urinary System. New Haven, Conn: Yale University Press; 1969.
63. Parnes W, Shuler PJ, Donaldson HM. Field Survey of Allied Chemical Corporation. Cincinnati, Ohio: National Institute for Occupational Safety and Health, Division of Field Studies and Clinical Investigations; October 16, 1972.
64. Murray WM. Affidavit concerning 3,3′ Dichlorobenzidine. May 15, 1973. Submitted to OSHA's Standards Advisory Committee on Carcinogens by Donald L. Morgan of Cleary, Gottlieb, Steen & Hamilton; June 26, 1973.
65. Ouellet-Hellstrom R, Rench JD. Bladder cancer incidence in acrylamine workers. J Occup Environ Med. 1996;38:1239-1247.
66. National Association of Manufacturers. Comments on OSHA's emergency temporary standard for certain carcinogens [Docket H-003] September 12, 1973.
67. Korbitz BC, on behalf of the Polyurethane Manufacturers Association. Comments on OSHA's proposed standard on 4,4′ methylene bis (2-chloroaniline) Docket H-050A. March 10, 1975.
68. Ward E, Halperin W, Thun M, et al. Bladder tumors in two young males occupationally exposed to MBOCA. Am J Ind Med. 1988;14:267-272.
69. Angiosarcoma of the liver among polyvinyl chloride workers. Morbidity and Mortality Weekly Report, February 9, 1974. Atlanta, GA: US Department of Health, Education and Welfare; 1974.
70. Forman D, Bennett B, Stafford J, Doll R. Exposure to vinyl chloride and angiosarcomas of the liver: a report of the register of cases. Br J Ind Med. 1985;42: 750-753.
71. Spirtas R, Kaminski R. Angiosarcoma of the liver in vinyl chloride/polyvinyl chloride workers:1977 update of the NIOSH register. J Occup Med. 1978;20: 427-429.
72. Delorme F, Theriault G. Ten cases of angiosarcoma of the liver in Shawinigan, Quebec. J Occup Med. 1978;20:338-340.
73. Brady J, Liberatore F, Harper P, et al. Angiosarcoma of the liver: an epidemiologic survey. J Natl Cancer Inst. 1977;59:1383-1385.
74. Wagoner JK, Infante PF. Vinyl chloride: a case for the use of laboratory bioassay in the regulatory control procedure. In: Hiatt HH, Watson JD, Winsten JA, eds. Origins of Human Cancer: Book C. Human Risk Assessment. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1977.
75. 39 Federal Register. 16896 (1974).
76. Vinyl chloride proposed standard. Vol. 39, No. 92, May 10, 1974, page 16896.
77. Moore J. Letter from Hill and Knowlton, Inc, to John Spano, Monsanto Company, with accompanying Recommendations for Public Affairs Program for SPI's Vinyl Chloride Committee. Phase I: Preparation for OSHA Hearing. Document No. 19740612_001_ 00004426. June 12, 1974. Available at: http://www. chemicalindustryarchives.org. Accessed December 1, 2003.
78. Ong EK, Glantz SA. Constructing "sound science" and "good epidemiology": Tobacco, lawyers, and public relations firms. Am J Public Health. 2001;91:1749-1758.
79. Huber PW. Galileo's Revenge. New York, NY: Basic Books; 1991.
80. JunkScience.com: all the junk that's fit to debunk. Available at: http://www.junkscience.com/define.htm. Accessed August 13, 2004.
81. Junk science at-large: junk scientists. Available at: http://www.junkscience.com/roster.html. Accessed August 13, 2004.
82. Luntz memo on the environment Available at Environmental Working Group at: http://www.ewg.org: 16080/briefings/luntzmemo. Accessed August 13, 2004.
83. National Academy of Sciences. Climate Change Science: An Analysis of Some Key Questions. Washington, DC: National Academies Press; 2001. Available at: http://books.nap.edu/books/0309075742/html. Accessed August 4, 2004.
84. National Academy of Sciences. Planning Climate and Global Change Research: A Review of the Draft U.S. Climate Change Science Program Strategic Plan. Washington, DC: National Academies Press; 2003.
85. Kennedy D. The policy drought on climate change. Science. 2003;299:309.
86. Edmond G, Mercer D. Trashing "junk science." Stan Tech L Rev. 1998;3.
87. Herrick CN, Jamieson D. Junk science and environmental policy: obscuring public debate with misleading discourse. Philos Public Policy Q. 2001;21: 11-16.
88. Kassirer JP, Cecil JS. Inconsistency in evidentiary standards for medical testimony. JAMA. 2002;288: 1382-1386.
89. FDA moves to end use of bromocriptine for postpartum breast engorgement. FDA news release, August 17, 1994. Available at: http://www.fda.gov/bbs/topics/ ANSWERS/ANS00594.html. Accessed August 11, 2004.
90. Berger MA. What has a decade of Daubert wrought? Am J Public Health. 2005;95:S59-S65.
91. Cecil JS. Ten years of judicial gatekeeping under Daubert. Am J Public Health. 2005;95:S74-S80.
92. Haack S. Trial and error: the Supreme Court's philosophy of science. Am J Public Health. 2005;95: S66-S73.
93. Cranor CF, Eastmond DA. Scientific ignorance and reliable patterns of evidence in toxic tort causation: is there a need for liability reform? Law Contemp Probs. 2001;64:5-48.
94. Edmond G, Mercer D. Daubert and the exclusionary ethos: the convergence of corporate and judicial attitudes towards the admissibility of expert evidence in tort litigation. Law & Policy. 2004;26:231-257.
95. Goldsmith WJ. Occupational Safety and Health Act's rulemaking procedures. Testimony presented before US House of Representatives, Subcommittee on Workforce Protections, House Committee on Education and the Workforce; June 14, 2001. http://edworkforce. house.gov/hearings/107th/wp/osha61401/goldsmith. htm. Accessed verified March 14, 2005.
96. Raul AC, Dwyer JZ. "Regulatory Daubert": A proposal to enhance judicial review of agency science by incorporating Daubert principles into administrative law. Law Contemp Probs. 2003;66:7-44.
97. McGarity TO. On the prospect of "Daubertizing" judicial review of risk assessment. Law Contemp Probs. 2003;66:155-225.
98. Wagner WE. Importing Daubert to administrative agencies through the information quality act. J Law Policy. 2004;12:589-617
99. US Chamber of Commerce. Scientific Information in Federal Rulemaking. Policy statement, January 2002. Available at: http://www.uschamber.com/ government/issues/regulatory/scientific_rulemaking.htm. Accessed August 13, 2004.
100. §514 and §516 of the Consolidated Appropriations Act of 2001, P.L. 106-554
101. Twohey M. Jim Tozzi: on jazz and OMB. The Federal Paper. November 18, 2002:1.
102. Tozzi J. Memorandum to Matthew Winokur, director of worldwide regulatory affairs, Philip Morris. Subject: Meeting with EPA officials on data access/data quality. January 11, 1999. Philip Morris Document 2065230935. Available at: http://tobaccodocuments. org/pm. Accessed December 4, 2003.
103. Tozzi J. Letter to Robert Elves, Philip Morris. February 29, 2000. Philip Morris Document 2072826830. Available at: http://tobaccodocumente.org/pm. Accessed December 4, 2003.
104. New Law Means More Federal Rules Can Be Challenged. The Center for Regulatory Effectiveness, CRE in the News. Available at: http://www.thecre.com/ news.html. Accessed December 8, 2003.
105. Morgan, Lewis & Brockius, LLP. Letter to US Environmental Protection Agency; August 19, 2003. Available at: http://www.epa.gov/oei/qualityguidelines/ afreqcorrectionsub/12467.pdf. Accessed December 8, 2003.
106. EPA notice about revising Guidance for Preventing Asbestos Disease Among Auto Mechanics ("Gold Book"). Available at: http://www.epa.gov/ asbestos/auto.html. Accessed August 13, 2004.
107. Snow J. On the mode of communication of cholera [published in 1855 in London]. In: Frost WH, ed. Snow on Cholera. New York, NY: The Commonwealth Fund; 1936.
108. Davidoff F, DeAngelis CD, Drazen JF, et al. Sponsorship, authorship, and accountability. JAMA. 2001; 286:1232.
109. Michaels D, Wagner W. Disclosures in regulatory science. Science. 2003;302:2073.
110. Hill AB. The environment and disease: association or causation? Proc Royal Soc Med 1965;58:295-300.